News

FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq HybrezaTM (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for subcutaneous (SC), under the skin injection for patients in the United States. Tecentriq Hybreza can be injected subcutaneously over approximately seven minutes, compared with 30-60 minutes for standard IV infusion of Tecentriq (atezolizumab). It will be available for all IV indications of Tecentriq approved for adults in the U.S., including certain types of lung, liver, skin and soft tissue cancer.

“By enabling subcutaneous administration for a cancer immunotherapy, Tecentriq Hybreza now offers patients with multiple cancer types and their physicians greater flexibility and choice of treatment administration,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “We are pleased to introduce this new subcutaneous formulation that builds on the established safety and efficacy profile of intravenous Tecentriq and can treat patients faster and in more accessible settings.”

“This approval represents a significant option to improve the patient experience,” said Ann Fish-Steagall, RN, senior vice president of Patient Services at the LUNGevity Foundation. “When patients have options, they feel empowered to be vital participants in their own care and choose their preferred treatment option.”

The FDA approval is based on pivotal data from the Phase IB/III IMscin001 study, which showed comparable levels of Tecentriq in the blood, when administered subcutaneously, and a safety and efficacy profile consistent with the IV formulation. The Phase II IMscin002 study showed that 71% of patients preferred Tecentriq Hybreza over intravenous atezolizumab, and the most common reasons were less time in the clinic, increased comfort during treatment and reduced emotional distress. 4 out of 5 patients (79%) chose Tecentriq Hybreza to continue their treatment, after experiencing both formulations.

Developing new formulations of our medicines is part of our commitment to improve the patient experience and support people living with different illnesses at every step of their treatment journey. With Tecentriq Hybreza and Roche/Genentech’s 13 other subcutaneous therapies – available across various diseases – we offer additional administration options to meet the diverse preferences of patients.

The subcutaneous formulation of Tecentriq received its first worldwide approval in Great Britain in August 2023 and is now approved in over 50 countries (outside the U.S. marketed as Tecentriq SC). Regulatory reviews in other countries and regions are ongoing.

Read more here.

Recent News

03/31/2025

Allozymes and Bonumose Collaborate to Accelerate Enzyme Innovations for Beneficial Food & Supplement Ingredients

Allozymes, a leader in protein engineering, and Bonumose, a leader in innovative enzyme combinations enabling the production of high-volume, healthy, naturally occurring monosaccharides from commodity feedstocks such as starch and sugar, announce the preliminary results of improvements to key enzymes for Bonumose’s ingredient production process. Bonumose enzyme breakthroughs include unique combinations converting plant-based starch and

03/26/2025

New survey: U.S. biotechs warn tariffs could impede access to cures, stifle innovation

Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical supply chain. According to the findings, nearly 90% of U.S. biotech companies rely on imported components for at least half of their FDA-approved products — making the supply of medicines for US patients and

03/25/2025

AgroSpheres Named on Both the World’s Top GreenTech Companies 2025 and America’s Top GreenTech Companies 2025 Lists by TIME Magazine

AgroSpheres has been named on both the World’s Top GreenTech Companies 2025 and America’s Top GreenTech Companies 2025 lists. These prestigious awards are presented by TIME and Statista Inc., the leading statistics portal and industry ranking provider. The award lists were announced on March 25th, 2025, and can be viewed on TIME’s website. Statista ranked